$599

Novo Discontinues Saxenda; Oral Wegovy Accepted for Review in China; Lilly Posts New China-Based Orfor Study; GSK Initiates New ALD Study

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Lilly, and GSK. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here